Overview

Safety and Toxicity Study of IMM27M in Patients With Advanced Solid Tumor

Status:
Not yet recruiting
Trial end date:
2023-08-18
Target enrollment:
Participant gender:
Summary
This is a single arm, open label, multi-center and fist in human dose escalation study, to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity in patients with advanced and metastatic solid tumor.
Phase:
Phase 1
Details
Lead Sponsor:
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd